UNITED STATES
	SECURITIES AND EXCHANGE COMMISSION
	Washington, D.C. 20549
	SCHEDULE 13D

 

Under the Securities Exchange Act of 1934
(Amendment No. 2)*

 

(Name of Issuer)

 

(Title of Class of Securities)

 

(CUSIP Number)

 

(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)

 

(Date of Event Which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), Rule 13d-1(f) or Rule 13d-1(g), check the following box. o

 

* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

 

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

 

2

 

 

3

 

 

4

 

This Amendment No. 2 to Schedule 13D (this “Amendment No. 2”) amends the statement on Schedule 13D relating to the Common Stock of the Issuer filed by the Reporting Persons with the Securities and Exchange Commission (the “Commission”) on March 5, 2018, as amended by Amendment No. 1 to Schedule 13D filed by the Reporting Persons with the Commission on April 3, 2018 (as so amended, the “Schedule 13D”). Capitalized terms used in this Amendment No. 2 but not otherwise defined herein have the meanings given to them in the Schedule 13D.

 

Except as otherwise set forth herein, this Amendment No. 2 does not modify any of the information previously reported by the Reporting Persons in the Initial Schedule 13D.

 

Item 4.                                                         Purpose of Transaction.

 

Item 4 of the Schedule 13D is hereby amended to add the following information:

 

In connection with the execution and delivery of the Agreement and Plan of Merger (the “Merger Agreement”), dated as of July 8, 2019, by and among the Issuer, AdaptHealth Holdings, LLC, a Delaware limited liability company (“AdaptHealth”), BM AH Holdings, LLC, a Delaware limited liability company, Access Point Medical, Inc, a Delaware corporation, DFB Merger Sub LLC, a Delaware limited liability company, AH Representative LLC, a Delaware limited liability company, and, solely for the limited purposes set forth therein, BlueMountain Foinaven Master Fund L.P., a Cayman Islands exempted limited partnership, BMSB L.P., a Delaware limited partnership, BlueMountain Fursan Fund L.P., a Cayman Islands exempted limited partnership, and Clifton Bay Offshore Investments, L.P., a British Virgin Islands limited partnership, the Sponsor entered into a letter agreement, dated July 8, 2019 (the “Letter Agreement”), pursuant to which the Sponsor agreed to transfer, immediately prior to the consummation of the transactions contemplated by the Merger Agreement and for no consideration, 2,500,000 Founder Shares and 1,733,333 Private Placement Warrants to AdaptHealth.

 

Item 6.                                                         Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.

 

Item 6 of the Schedule 13D is hereby amended to add the following information:

 

Pursuant to the Merger Agreement, and in order to induce DFB Healthcare and AdaptHealth to enter into the Merger Agreement and proceed with the consummation of the transactions contemplated thereby, the Sponsor entered into the Letter Agreement pursuant to which the Sponsor agreed to transfer, immediately prior to the consummation of the transactions contemplated by the Merger Agreement and for no consideration, 2,500,000 Founder Shares and 1,733,333 Private Placement Warrants to AdaptHealth.

 

Item 7.                                                         Material to be Filed as Exhibits

 

Item 7 of the Schedule 13D is hereby amended to add the following information:

 

13                                                                                  Letter Agreement, dated July 8, 2019, by and among Deerfield/RAB Ventures, LLC, AdaptHealth Holdings, LLC and the Issuer (incorporated by reference to Exhibit 10.3 to the Issuer’s Current Report on Form 8-K filed with the SEC on July 12, 2019).

 

5

 

SIGNATURES

 

After reasonable inquiry and to the best of his or its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

 

	Date: July 12, 2019
	DEERFIELD/RAB VENTURES, LLC
	By:	/s/ Richard Barasch*
		Name: Richard Barasch
		Title:   Manager
		/s/ Richard Barasch*
		Name: Richard Barasch
	RAB VENTURES (DFB) LLC
	By:	/s/ Richard Barasch*
		Name: Richard Barasch
		Title:   Manager
	*By:	/s/ Alan I. Annex
		Name: Alan I. Annex
		Attorney-in-Fact

 

6